S&P 500   4,361.49 (-1.84%)
DOW   34,341.82 (-1.51%)
QQQ   360.39 (-2.69%)
AAPL   142.14 (-2.22%)
MSFT   284.99 (-3.12%)
FB   340.59 (-3.67%)
GOOGL   2,718.52 (-3.65%)
TSLA   779.14 (-1.54%)
AMZN   3,303.73 (-3.00%)
NVDA   207.60 (-4.16%)
BABA   150.61 (+0.29%)
NIO   35.12 (-4.49%)
CGC   14.21 (-3.40%)
GE   105.46 (+0.10%)
MU   73.57 (-2.14%)
AMD   102.60 (-5.14%)
T   27.26 (-0.51%)
F   14.43 (+1.91%)
ACB   6.74 (+5.48%)
DIS   174.61 (-2.05%)
PFE   42.99 (-1.33%)
BA   219.29 (-2.17%)
AMC   37.48 (-4.63%)
S&P 500   4,361.49 (-1.84%)
DOW   34,341.82 (-1.51%)
QQQ   360.39 (-2.69%)
AAPL   142.14 (-2.22%)
MSFT   284.99 (-3.12%)
FB   340.59 (-3.67%)
GOOGL   2,718.52 (-3.65%)
TSLA   779.14 (-1.54%)
AMZN   3,303.73 (-3.00%)
NVDA   207.60 (-4.16%)
BABA   150.61 (+0.29%)
NIO   35.12 (-4.49%)
CGC   14.21 (-3.40%)
GE   105.46 (+0.10%)
MU   73.57 (-2.14%)
AMD   102.60 (-5.14%)
T   27.26 (-0.51%)
F   14.43 (+1.91%)
ACB   6.74 (+5.48%)
DIS   174.61 (-2.05%)
PFE   42.99 (-1.33%)
BA   219.29 (-2.17%)
AMC   37.48 (-4.63%)
S&P 500   4,361.49 (-1.84%)
DOW   34,341.82 (-1.51%)
QQQ   360.39 (-2.69%)
AAPL   142.14 (-2.22%)
MSFT   284.99 (-3.12%)
FB   340.59 (-3.67%)
GOOGL   2,718.52 (-3.65%)
TSLA   779.14 (-1.54%)
AMZN   3,303.73 (-3.00%)
NVDA   207.60 (-4.16%)
BABA   150.61 (+0.29%)
NIO   35.12 (-4.49%)
CGC   14.21 (-3.40%)
GE   105.46 (+0.10%)
MU   73.57 (-2.14%)
AMD   102.60 (-5.14%)
T   27.26 (-0.51%)
F   14.43 (+1.91%)
ACB   6.74 (+5.48%)
DIS   174.61 (-2.05%)
PFE   42.99 (-1.33%)
BA   219.29 (-2.17%)
AMC   37.48 (-4.63%)
S&P 500   4,361.49 (-1.84%)
DOW   34,341.82 (-1.51%)
QQQ   360.39 (-2.69%)
AAPL   142.14 (-2.22%)
MSFT   284.99 (-3.12%)
FB   340.59 (-3.67%)
GOOGL   2,718.52 (-3.65%)
TSLA   779.14 (-1.54%)
AMZN   3,303.73 (-3.00%)
NVDA   207.60 (-4.16%)
BABA   150.61 (+0.29%)
NIO   35.12 (-4.49%)
CGC   14.21 (-3.40%)
GE   105.46 (+0.10%)
MU   73.57 (-2.14%)
AMD   102.60 (-5.14%)
T   27.26 (-0.51%)
F   14.43 (+1.91%)
ACB   6.74 (+5.48%)
DIS   174.61 (-2.05%)
PFE   42.99 (-1.33%)
BA   219.29 (-2.17%)
AMC   37.48 (-4.63%)
NYSE:NVO

Novo Nordisk A/S Stock Forecast, Price & News

$95.33
-3.75 (-3.78 %)
(As of 09/28/2021 01:26 PM ET)
Add
Compare
Today's Range
$94.84
$96.63
50-Day Range
$87.51
$106.62
52-Week Range
$63.22
$107.24
Volume18,264 shs
Average Volume987,301 shs
Market Capitalization$224.48 billion
P/E Ratio31.15
Dividend Yield0.76%
Beta0.41
30 days | 90 days | 365 days | Advanced Chart
Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.


Novo Nordisk A/S logo

About Novo Nordisk A/S

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
45,323
Year Founded
1923

Sales & Book Value

Annual Sales
$19.45 billion
Cash Flow
$2.98 per share
Book Value
$4.12 per share

Profitability

Net Income
$6.46 billion

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares
2,354,800,000
Market Cap
$224.48 billion
Next Earnings Date
10/29/2021 (Estimated)
Optionable
Optionable

Social Links


MarketRank

Overall MarketRank

1.38 out of 5 stars

Medical Sector

1086th out of 1,353 stocks

Pharmaceutical Preparations Industry

528th out of 666 stocks

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -












Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

Is Novo Nordisk A/S a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Novo Nordisk A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.
View analyst ratings for Novo Nordisk A/S
or view top-rated stocks.

What stocks does MarketBeat like better than Novo Nordisk A/S?

Wall Street analysts have given Novo Nordisk A/S a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Novo Nordisk A/S wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Novo Nordisk A/S?

Novo Nordisk A/S saw a drop in short interest during the month of August. As of August 13th, there was short interest totaling 2,890,000 shares, a drop of 30.5% from the July 29th total of 4,160,000 shares. Based on an average trading volume of 956,700 shares, the days-to-cover ratio is currently 3.0 days. Currently, 0.2% of the company's shares are short sold.
View Novo Nordisk A/S's Short Interest
.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Friday, October 29th 2021.
View our earnings forecast for Novo Nordisk A/S
.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) issued its earnings results on Tuesday, August, 3rd. The company reported $5.26 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.76 by $4.50. The company earned $5.35 billion during the quarter, compared to analyst estimates of $5.21 billion. Novo Nordisk A/S had a net margin of 34.17% and a trailing twelve-month return on equity of 72.72%.
View Novo Nordisk A/S's earnings history
.

How has Novo Nordisk A/S's stock price been impacted by COVID-19?

Novo Nordisk A/S's stock was trading at $57.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVO shares have increased by 64.6% and is now trading at $95.28.
View which stocks have been most impacted by COVID-19
.

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S declared a semi-annual dividend on Friday, August 6th. Shareholders of record on Tuesday, August 17th will be given a dividend of $0.5571 per share on Wednesday, August 25th. This represents a yield of 1.1%. The ex-dividend date of this dividend is Monday, August 16th.
View Novo Nordisk A/S's dividend history
.

Is Novo Nordisk A/S a good dividend stock?

Novo Nordisk A/S pays an annual dividend of $0.77 per share and currently has a dividend yield of 0.76%. The dividend payout ratio of Novo Nordisk A/S is 27.90%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 21.81% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.
View Novo Nordisk A/S's dividend history.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?

Novo Nordisk A/S issued an update on its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $21.80 billion-$22.42 billion, compared to the consensus revenue estimate of $21.47 billion.

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the following people:
  • Lars Fruergaard Jørgensen, President & Chief Executive Officer
  • Maziar Mike Doustdar, Executive Vice President-International Operations
  • Karsten Munk Knudsen, Chief Financial Officer & Executive Vice President
  • Mads Krogsgaard Thomsen, Chief Science Officer & Executive Vice President
  • Henrik Ehlers Wulff, Executive VP & Head-Information Technology

What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?

372 employees have rated Novo Nordisk A/S CEO Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among Novo Nordisk A/S's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.03%), Fisher Asset Management LLC (0.68%), Bank of America Corp DE (0.31%), Bank of America Corp DE (0.31%), Capital International Investors (0.23%) and Folketrygdfondet (0.20%).
View institutional ownership trends for Novo Nordisk A/S
.

Which institutional investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Northern Trust Corp, Alyeska Investment Group L.P., Wells Fargo & Company MN, Bank of America Corp DE, Bank of America Corp DE, BlackRock Inc., and First Trust Advisors LP.
View insider buying and selling activity for Novo Nordisk A/S
or view top insider-selling stocks.

Which institutional investors are buying Novo Nordisk A/S stock?

NVO stock was purchased by a variety of institutional investors in the last quarter, including Amundi, Folketrygdfondet, Bank of Montreal Can, Clark Capital Management Group Inc., Capital International Investors, Goldman Sachs Group Inc., Russell Investments Group Ltd., and Morgan Stanley.
View insider buying and selling activity for Novo Nordisk A/S
or or view top insider-buying stocks.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $95.28.

How much money does Novo Nordisk A/S make?

Novo Nordisk A/S has a market capitalization of $224.37 billion and generates $19.45 billion in revenue each year. The company earns $6.46 billion in net income (profit) each year or $2.76 on an earnings per share basis.

How many employees does Novo Nordisk A/S have?

Novo Nordisk A/S employs 45,323 workers across the globe.

Does Novo Nordisk A/S have any subsidiaries?

The following companies are subsidiares of Novo Nordisk A/S: Aldaph SpA, Beijing Novo Nordisk Pharmaceuticals Science & Technology Co. Ltd., Calibrium, Churchill Stateside Solar Fund XIV LLC, Corvidia, Emisphere Technologies, MB2 LLC, NNE A/S, Novo Investment Pte Limited, Novo Nordisk, Novo Nordisk (China) Pharmaceuticals Co. Ltd., Novo Nordisk (Pty) Limited, Novo Nordisk B.V., Novo Nordisk Biopharm Limited, Novo Nordisk Canada Inc., Novo Nordisk Colombia SAS, Novo Nordisk Comercio Produtos Farmaceuticos Lda., Novo Nordisk Denmark A/S, Novo Nordisk Egypt LLC, Novo Nordisk Farma OY, Novo Nordisk Farma S.R.L., Novo Nordisk Farma dooel, Novo Nordisk Farmacéutica Limitada, Novo Nordisk Farmacêutica do Brasil Ltda., Novo Nordisk Health Care AG, Novo Nordisk Hellas Epe., Novo Nordisk Holding Limited, Novo Nordisk Hong Kong Limited, Novo Nordisk Hrvatska d.o.o., Novo Nordisk Hungaria Kft., Novo Nordisk Inc., Novo Nordisk India Private Limited, Novo Nordisk Kazakhstan LLP, Novo Nordisk Kenya Ltd., Novo Nordisk Lanka (PVT) Ltd, Novo Nordisk Limited, Novo Nordisk Limited Liability Company, Novo Nordisk Ltd, Novo Nordisk Mexico S.A. de C.V., Novo Nordisk Panama S.A., Novo Nordisk Pars, Novo Nordisk Peru S.A.C., Novo Nordisk Pharma (Malaysia) Sdn Bhd, Novo Nordisk Pharma (Private) Limited, Novo Nordisk Pharma (Singapore) Pte Ltd., Novo Nordisk Pharma (Taiwan) Ltd., Novo Nordisk Pharma (Thailand) Ltd., Novo Nordisk Pharma AG, Novo Nordisk Pharma Argentina S.A., Novo Nordisk Pharma EAD, Novo Nordisk Pharma GmbH, Novo Nordisk Pharma Gulf FZ-LLC, Novo Nordisk Pharma Inc., Novo Nordisk Pharma Korea Ltd., Novo Nordisk Pharma Limited, Novo Nordisk Pharma Ltd., Novo Nordisk Pharma Operations (Business Area) Sdn Bhd, Novo Nordisk Pharma Operations A/S, Novo Nordisk Pharma S.A., Novo Nordisk Pharma SARL, Novo Nordisk Pharma SAS, Novo Nordisk Pharma d.o.o., Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Pharmaceutical Services Sp. z o.o., Novo Nordisk Pharmaceuticals (Philippines) Inc., Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk Pharmaceuticals Pty. Ltd., Novo Nordisk Pharmatech A/S, Novo Nordisk Production SAS, Novo Nordisk Production Support LLC, Novo Nordisk Produção Farmacêutica do Brasil Ltda., Novo Nordisk Region AAMEO and LATAM A/S, Novo Nordisk Region Europe A/S, Novo Nordisk Region Japan & Korea A/S, Novo Nordisk Research Center Indianapolis Inc., Novo Nordisk Research Center Seattle Inc., Novo Nordisk S.P.A., Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Novo Nordisk Scandinavia AB, Novo Nordisk Scandinavia AS, Novo Nordisk Service Centre (India) Pvt. Ltd., Novo Nordisk Slovakia s.r.o., Novo Nordisk Tunisie SARL, Novo Nordisk US Bio Production Inc., Novo Nordisk US Holdings Inc., Novo Nordisk Ukraine LLC, Novo Nordisk Venezuela Casa de Representacion C.A., Novo Nordisk d.o.o., Novo Nordisk s.r.o., PT. Novo Nordisk Indonesia, S.A. Novo Nordisk Pharma N.V., UAB Novo Nordisk Pharma, Xellia Pharmaceuticals, and Ziylo.

When was Novo Nordisk A/S founded?

Novo Nordisk A/S was founded in 1923.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is www.novonordisk.com.

Where are Novo Nordisk A/S's headquarters?

Novo Nordisk A/S is headquartered at Novo Alle, Bagsvaerd G7, 2880.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at (454) 444-8888 or via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.